The effect of randomness for dependency map on the robustness of interdependent lattices

ACKNOWLEDGMENTS This paper is supported by the National Natural Science Foundation of China (Grant Nos. 61573067 and 61472045), the Beijing Higher Education Young Elite Teacher Project (Grant No. YETP0449), the Asia Foresight Program under NSFC Grant (Grant No. 61411146001), and the Beijing Natural Science Foundation (Grant No. 4142016).Peer reviewedPublisher PD

XCR1 expression distinguishes human conventional dendritic cell type 1 with full effector functions from their immediate precursors

Dendritic cells (DCs) are major regulators of innate and adaptive immune responses. DCs can be classified into plasmacytoid DCs and conventional DCs (cDCs) type 1 and 2. Murine and human cDC1 share the mRNA expression of XCR1. Murine studies indicated a specific role of the XCR1-XCL1 axis in the induction of immune responses. Here, we describe that human cDC1 can be distinguished into XCR1$^{-}$ and XCR1$^{+}$ cDC1 in lymphoid as well as nonlymphoid tissues. Steady-state XCR1$^{+}$ cDC1 display a preactivated phenotype compared to XCR1$^{-}$ cDC1. Upon stimulation, XCR1$^{+}$ cDC1, but not XCR1$^{-}$ cDC1, secreted high levels of inflammatory cytokines as well as chemokines. This was associated with enhanced activation of NK cells mediated by XCR1$^{+}$ cDC1. Moreover, XCR1$^{+}$ cDC1 excelled in inhibiting replication of Influenza A virus. Further, under DC differentiation conditions, XCR1$^{-}$ cDC1 developed into XCR1$^{+}$ cDC1. After acquisition of XCR1 expression, XCR1$^{-}$ cDC1 secreted comparable level of inflammatory cytokines. Thus, XCR1 is a marker of terminally differentiated cDC1 that licenses the antiviral effector functions of human cDC1, while XCR1$^{-}$ cDC1 seem to represent a late immediate precursor of cDC1

Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection

We explored the possibility to target Ewing's sarcoma family of tumors (ESFT) by redirecting T cells. To this aim, we considered NKG2D-ligands (NKG2D-Ls) as possible target antigens. Detailed analysis of the expression of MICA, MICB, ULBP-1, -2, and -3 in fourteen ESFT cell lines revealed consistent expression of at least one NKG2D-L. Thus, for redirecting T cells, we fused a CD3ζ/CD28-derived signaling domain to the ectodomain of NKG2D, however, opposite transmembrane orientation of this signaling domain and NKG2D required inverse orientation fusion of either of them. We hypothesized that the particularly located C-terminus of the NKG2D ectodomain should allow reengineering of the membrane anchoring from a native N-terminal to an artificial C-terminal linkage. Indeed, the resulting chimeric NKG2D receptor (chNKG2D) was functional and efficiently mediated ESFT cell death triggered by activated T cells. Notably, ESFT cells with even low NKG2D-L expression were killed by CD8pos and also CD4pos cells. Both, mRNA transfection and lentiviral transduction resulted in high level surface expression of chNKG2D. However, upon target-cell recognition receptor surface levels were maintained by tranfected RNA only during the first couple of hours after transfection. Later, target-cell contact resulted in strong and irreversible receptor down-modulation, whereas lentivirally mediated expression of chNKG2D remained constant under these conditions. Together, our study defines NKG2D-Ls as targets for a CAR-mediated T cell based immunotherapy of ESFT. A comparison of two different methods of gene transfer reveals strong differences in the susceptibility to ligand-induced receptor down-modulation with possible implications for the applicability of RNA transfection